Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies

A systematic review

Austin H. Nguyen, Sheila B. Bhavsar, Erinn M. Riley, Gabriel C. Caponetti, Devendra K. Agrawal

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.

Original languageEnglish (US)
Pages (from-to)425-429
Number of pages5
JournalWspolczesna Onkologia
Volume20
Issue number6
DOIs
StatePublished - 2016

Fingerprint

Hematologic Neoplasms
Neoplasms
Nuclear Proteins
Advanced Glycosylation End Product-Specific Receptor
PubMed

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies : A systematic review. / Nguyen, Austin H.; Bhavsar, Sheila B.; Riley, Erinn M.; Caponetti, Gabriel C.; Agrawal, Devendra K.

In: Wspolczesna Onkologia, Vol. 20, No. 6, 2016, p. 425-429.

Research output: Contribution to journalReview article

@article{9d7c06da8b5742f8a6cb7575d2f64c95,
title = "Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: A systematic review",
abstract = "High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.",
author = "Nguyen, {Austin H.} and Bhavsar, {Sheila B.} and Riley, {Erinn M.} and Caponetti, {Gabriel C.} and Agrawal, {Devendra K.}",
year = "2016",
doi = "10.5114/wo.2016.65600",
language = "English (US)",
volume = "20",
pages = "425--429",
journal = "Wspolczesna Onkologia",
issn = "1428-2526",
publisher = "Termedia Publishing House Ltd.",
number = "6",

}

TY - JOUR

T1 - Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies

T2 - A systematic review

AU - Nguyen, Austin H.

AU - Bhavsar, Sheila B.

AU - Riley, Erinn M.

AU - Caponetti, Gabriel C.

AU - Agrawal, Devendra K.

PY - 2016

Y1 - 2016

N2 - High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.

AB - High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.

UR - http://www.scopus.com/inward/record.url?scp=85014040836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014040836&partnerID=8YFLogxK

U2 - 10.5114/wo.2016.65600

DO - 10.5114/wo.2016.65600

M3 - Review article

VL - 20

SP - 425

EP - 429

JO - Wspolczesna Onkologia

JF - Wspolczesna Onkologia

SN - 1428-2526

IS - 6

ER -